10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ABBOTT LABORATORIES | |||
Ticker: ABT Fiscal Year: 2009 | |||
Consolidated Statement of Earnings | |||
Period Ending Dec 31, 2009 10-K (Filed: Feb 19, 2010) | |||
| (In Thousands) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2009 | Dec 31, 2008 | Dec 31, 2007 | |
| Net Sales | $ 30,764,707 | 29,527,552 | 25,914,238 |
| Cost of products sold | 13,209,329 | 12,612,022 | 11,422,046 |
| Research and development | 2,743,733 | 2,688,811 | 2,505,649 |
| Acquired in-process research and development | 170,000 | 97,256 | |
| Selling, general and administrative | 8,405,904 | 8,435,624 | 7,407,998 |
| Total Operating Cost and Expenses | 24,528,966 | 23,833,713 | 21,335,693 |
| Operating Earnings | 6,235,741 | 5,693,839 | 4,578,545 |
| Interest expense | 519,656 | 528,474 | 593,142 |
| Interest (income) | (137,779) | (201,229) | (136,752) |
| (Income) from the TAP Pharmaceutical Products Inc. joint venture | (118,997) | (498,016) | |
| Net foreign exchange (gain) loss | 35,584 | 84,244 | 14,997 |
| Other (income) expense, net | (1,375,494) | (454,939) | 135,526 |
| Earnings from Continuing Operations Before Taxes | 7,193,774 | 5,856,286 | 4,469,648 |
| Taxes on Earnings from Continuing Operations | 1,447,936 | 1,122,070 | 863,334 |
| Earnings from Continuing Operations | 5,745,838 | 4,734,216 | 3,606,314 |
| Gain on Sale of Discontinued Operations, net of taxes | 146,503 | ||
| Net Earnings | 5,745,838 | 4,880,719 | 3,606,314 |
| Basic Earnings Per Common Share -- | |||
| Continuing Operations (in dollars per share) | 3.71 | 3.06 | 2.34 |
| Gain on Sale of Discontinued Operations, net of taxes (in dollars per share) | 0.10 | ||
| Net Earnings (in dollars per share) | 3.71 | 3.16 | 2.34 |
| Diluted Earnings Per Common Share -- | |||
| Continuing Operations (in dollars per share) | 3.69 | 3.03 | 2.31 |
| Gain on Sale of Discontinued Operations, net of taxes (in dollars per share) | 0.09 | ||
| Net Earnings (in dollars per share) | 3.69 | 3.12 | 2.31 |
| Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares) | 1,546,983 | 1,545,355 | 1,543,082 |
| Dilutive Common Stock Options and Awards (in shares) | 8,143 | 15,398 | 16,975 |
| Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options and Awards (in shares) | 1,555,126 | 1,560,753 | 1,560,057 |
| Outstanding Common Stock Options Having No Dilutive Effect (in shares) | 66,189 | 30,579 | 6,406 |
| External Links | |
| ABBOTT LABORATORIES (ABT) Fiscal Year 2009 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |